Trial Profile
A Phase II, Open-Label, Multicenter, Multicohort Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
- Indications Head and neck cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Roche
- 09 Jul 2020 Status changed from active, no longer recruiting to completed.
- 29 Jun 2020 Planned End Date changed from 26 Jan 2021 to 14 Jul 2020.
- 07 Mar 2020 This trial has been completed in Germany, according to European Clinical Trials Database record.